Let's Connect

News

ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study

By Industry News 1 min read

​Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.  — From Psychiatric Times articles Read More

Share this post
All News posts
News Industry News 10:00 am Talking With Titans: Sheldon Preskorn, MD, on the Evolution of Psychopharmacology ​Experts discuss psychopharmacology from discovery of CYP enzymes to modern serum testing.  — From Psychiatric Times articles Read More News Industry News 9:20 am Our Continued Evolution ​Discover expanded psychiatry coverage with new podcasts, interactive digital issues, and event reporting—we are your always-on media hub delivering fresh insights year-round.  — From Psychiatric Times articles Read More News Industry News 11:52 am The Ozempic Dilemma: Promises and Pitfalls in Psychiatry ​GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.  — From Psychiatric Times articles Read More

Integrated Psychiatric Consultants

Office Hours:
Mon-Fri, 9 a.m. - 5 p.m. CT

Follow us

Reach out today.

Integrated Psychiatric Consultants (IPC) is committed to protecting and respecting your privacy. Our team will use the information collected here solely to serve your needs and notify you about relevant services. To consent, please check the box above and submit this form.

Please note, this consent applies to all forms of communications, including SMS. If you have provided a mobile phone number above, you agree to receiving SMS messages from IPC. You may unsubscribe at any time. Message frequency varies. Messaging and data rates may apply. Reply STOP to cancel. For more information, please review our Privacy Policy.